UCB SA (UCBJY) Stock Price & Analysis
UCB SA (UCBJY) is trading at USD 152.13, up 5.13% today, as of October 23, 2026 at 15:52 UTC (US market open; quotes may be delayed), according to Nexqual market data.
UCBJY last closed at USD 144.7; today's session has ranged USD 147.59–152.13 on volume of 4,598 shares. Market capitalization is $57.92B, with a 52-week range of USD 110.55–168.76 (PNK). Source: Nexqual, retrieved October 23, 2026 at 16:42 UTC.
Also available as compact Markdown for AI agents: nexqual.com/UCBJY.md
Key facts (UCBJY)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 173.42 (range 161.93–184.92).
- Total return with dividends: 1Y +6.7% vs S&P 500 +14.6%; 5Y +167.5% vs S&P 500 +77.3%.
Analysts (UCBJY)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 173.42 (low 161.93, high 184.92).
Total return (dividends reinvested) (UCBJY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +6.7% | +167.5% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | +6.7% | +21.8% |
| Volatility (annualized) | 40.9% | 34.1% |
| Max drawdown | -33.7% (Feb 2026→Oct 2026) | -45.9% (Apr 2022→Sep 2022) |
UCBJY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2026) | $6.32 | $5.52 | +14.3% | $8.77B | 2 |
| Next fiscal year (ends Dec 2027) | $7.08 | $6.73 | +5.1% | $9.72B | 2 |
Key Statistics (as of October 23, 2026 at 16:42 UTC)
| Price | USD 152.13 |
|---|---|
| Change | ▲ 5.13% (up) |
| Previous Close | USD 144.7 |
| Open | USD 147.71 |
| Day Range | USD 147.59 – 152.13 |
| 52-Week Range | USD 110.55 – 168.76 |
| Volume | 4,598 shares |
| Market Cap | $57.92B |
| Exchange | PNK |
Technical Analysis (UCBJY)
Nexqual's technical model rates UCBJY "BUY" based on 5 bullish and 3 bearish signals across 128 daily candles, as of October 23, 2026 at 16:42 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 80.71 (overbought) |
| vs SMA50 | Above (USD 121.65) |
| MACD | 3.65 (positive) |
Analyst Ratings (UCBJY)
Wall Street analysts rate UCBJY "Buy" based on 2 analysts, with a mean price target of USD 173.42 (range USD 161.93–184.92), per Nexqual as of October 23, 2026 at 16:42 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 173.42 |
| High Target | USD 184.92 |
| Low Target | USD 161.93 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (UCBJY)
Source: Nexqual, October 23, 2026 at 16:42 UTC.
Financials & Fundamentals (UCBJY)
| Total Revenue | $8.52B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +22.50% |
| Gross Margin | +76.22% |
| Operating Margin | +33.33% |
| Profit Margin | +25.74% |
| ROE | +20.57% |
| Debt / Equity | 0.31 |
| Current Ratio | 1.2 |
| Total Cash | $766.00M |
| Total Debt | $3.59B |
Source: Nexqual, October 23, 2026 at 16:42 UTC.
Financial Health Score (UCBJY)
Nexqual rates UCB SA's overall financial health "Strong" across five dimensions, as of October 23, 2026 at 16:42 UTC.
| Growth | Strong — Revenue +26% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 76%, operating 33% (last 12 months) |
| Balance Sheet | Solid — EUR 766M cash vs EUR 3.59B debt |
| Cash Flow | Solid — Operating cash flow EUR 1.95B (TTM) |
| Efficiency | Strong — ROE 21%, ROA 8.3% |
Ownership (UCBJY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.02% |
| Shares Outstanding | 380.72M |
| Float | 240.20M |
Source: Nexqual, October 23, 2026 at 16:42 UTC.
Leadership (UCBJY)
UCB SA is led by Jean-Christophe Tellier, CEO & Executive Director, per Nexqual as of October 23, 2026 at 16:42 UTC.
| CEO & Executive Director | Jean-Christophe Tellier |
|---|---|
| Executive VP & CFO | Sandrine Dufour |
| Executive VP & Chief Scientific Officer | Alistair Henry |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARGX | argenx SE | USD 879.5 | ▲ 0.43% |
| ONC | BeOne Medicines Ltd. | USD 376.76 | ▼ 1.44% |
| MRNA | Moderna, Inc. | USD 206.32 | ▲ 1.82% |
| RVMD | Revolution Medicines, Inc. | USD 188.72 | ▲ 0.55% |
| REGN | Regeneron Pharmaceuticals, Inc. | USD 809.6 | ▼ 1.16% |
| RPRX | Royalty Pharma plc | USD 63.63 | ▼ 0.2% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:42 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt